29 January 2026
: Case report 
Takotsubo Syndrome Triggered by Immune Checkpoint Inhibitor-Induced Pneumonitis: A Multidisciplinary Diagnostic and Therapeutic Challenge
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons
Marco Kaldas ABDE 1,2*, Moneal Shah DF 1, Valentyna Ivanova ADF 1, Saed Alnaimat
E 1, Diana Pashaieva CG 2, Ronald Williams B 1, Anita Radhakrishnan ADEF 1
DOI: 10.12659/AJCR.950756
Am J Case Rep 2026; 27:e950756
Table 1 Timeline of key diagnostic and therapeutic events.
| Day | Event/findings |
|---|---|
| −9 | Initiated carboplatin + paclitaxel + pembrolizumab |
| 0 | Dyspnea, chest pain; ECG = RBBB + ST elevation; hs-T 424 ng/L; CT = bilateral opacities |
| 0 | Coronary angiography → normal ();Figure 5 |
| 1 | CMR → LVEF 32%, apical edema ↑, no LGE (–)Figures 2 |
| 2 | EMB 4 samples → fibrosis only ()Figure 6 |
| 3 | Started corticosteroids + GDMT (metoprolol, sacubitril/valsartan) |
| 5 | Troponins decreasing; symptoms improving |
| 14 | Discharged; MDT cleared re-challenge with pembrolizumab |
| 56 | Follow-up TTE → LVEF 60%, normal wall motion |